Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

When Patients With Chronic HBV Infection Do Not Meet Indications for Immediate Treatment: The Critical Role of Ongoing Monitoring

In this podcast, CCO’s expert faculty discusses how to identify which patients with chronic HBV infection may not need immediate HBV treatment and the critical need to continue monitoring such patients even in the absence of ongoing therapy.
person default
Pietro Lampertico, MD, PhD
Released: May 26, 2022

In this episode, Pietro Lampertico, MD, PhD, discusses what to do when treatment for hepatitis B virus (HBV) infection is not indicated, covering topics such as:

  • The different phases of chronic HBV infection
  • Which patients in different phases require immediate HBV treatment and which can be monitored without therapy
  • The critical importance of ongoing monitoring for patients who do not meet indications for immediate therapy
  • The tests and frequency that should be used for monitoring patients not receiving HBV treatment

Information on this Educational Activity

Faculty

Pietro Lampertico, MD, PhD

Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy

Pietro Lampertico, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Aligos, Antios, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, and Myr Pharma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings